Supplementary material

Supplementary Table 1. Comparison of PD-1 in VEGF, CD4+ T cells and CD8+ T cells between both groups.

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Group | VEGF/(ng/L) | t value | *p* value | CD4+ T cells PD-1/% | t value | *p* value | CD8+ T cells PD-1/% | t value | *p* value |
| Pre-treatment | Post-treatment | Pre-treatment | Post-treatment | Pre-treatment | Post-treatment |
| Group B (n = 44) | 623.25 ± 66.26 | 441.36 ± 33.95 | 16.21 | 0.0000 | 32.25 ± 3.16 | 18.06 ± 1.76 | 26.02 | 0.00 | 35.26 ± 3.16 | 27.91 ± 2.11 | 12.83 | 0.00 |
| Group A (n = 44) | 622.95 ± 59.36 | 552.31 ± 44.25 | 6.33 | 0.0000 | 33.07 ± 3.04 | 22.06 ± 2.11 | 19.74 | 0.00 | 34.95 ± 3.08 | 31.25 ± 3.14 | 5.58 | 0.00 |
| *t* value | 0.022 | 13.20 | — | — | 1.27 | 9.66 | — | — | 0.47 | 5.86 | — | — |
| *p* value | 0.98 | 0.00 | — | — | 0.21 | 0.00 | — | — | 0.64 | 0.00 | — | — |

 VEGF: vascular endothelial growth factor; CD4+: Cluster of differentiation 4+; CD8+ T: cytotoxic Tlymphocyte.

Supplementary Table 2. Comparison of immune function indicators between two groups.

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Group | CD3+ | t value | *p* value | CD4+ | t value | *p* value | CD4+/CD8+ | t value | *p* value |
| Pre-treatment | Post-treatment | Pre-treatment | Post-treatment | Pre-treatment | Post-treatment |
| Group B (n = 44) | 61.25 ± 4.21 | 65.35 ± 4.33 | 4.50 | 0.00 | 30.15 ± 2.56 | 36.33 ± 2.61 | 11.21 | 0.00 | 1.36 ± 0.21 | 1.86 ± 0.45 | 6.68 | 0.00 |
| Group A (n = 44) | 62.09 ± 4.56 | 57.35 ± 3.26 | 5.61 | 0.00 | 30.24 ± 2.41 | 27.35 ± 2.34 | 5.71 | 0.00 | 1.38 ± 0.23 | 1.23 ± 0.18 | 3.41 | 0.00 |
| *t* value | 0.90 | 9.79 | — | — | 0.17 | 16.99 | — | — | 0.43 | 8.62 | — | — |
| *p* value | 0.37 | 0.00 | — | — | 0.87 | 0.00 | — | — | 0.67 | 0.00 | — | — |

 CD3+: leukocyte differentiation antigen 3; CD4+: Cluster of differentiation 4+; CD8+ T: cytotoxic Tlymphocyte.

Supplementary Table 3. Comparison of tumor marker indicators between two groups.

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Group | CA50 (U/mL) | t value | *p* value | CEA (ng/mL) | t value | *p* value | CYFRA21-1 (ng/mL) | t value | *p* value |
| Pre-treatment | Post-treatment | Pre-treatment | Post-treatment | Pre-treatment | Post-treatment |
| Group B (n = 44) | 27.51 ± 0.23 | 14.35 ± 0.22 | 274.27 | 0.00 | 24.35 ± 0.21 | 9.84 ± 0.22 | 316.46 | 0.00 | 5.77 ± 0.43 | 2.04 ± 0.22 | 51.22 | 0.00 |
| Group A (n = 44) | 28.06 ± 0.26 | 20.17 ± 0.24 | 147.91 | 0.00 | 24.44 ± 0.19 | 15.34 ± 0.16 | 243.01 | 0.00 | 5.79 ± 0.44 | 3.64 ± 0.31 | 26.50 | 0.00 |
| t value | 10.51 | 118.58 | — | — | 1.31 | 134.11 | — | — | 0.22 | 27.92 | — | — |
| *p* value | 0.00 | 0.00 | — | — | 0.19 | 0.00 | — | — | 0.83 | 0.00 | — | — |

CA50: Carbohydrate antigen 50; CEA: carcinoembryonic antigen; CYFRA21-1: cytokeratin 19 fragment.